Advertisement

Drug Safety

, Volume 8, Issue 2, pp 99–127 | Cite as

Adverse Drug Interactions with Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

Recognition, Management and Avoidance
  • Anthony G. Johnson
  • Peter Seideman
  • Richard O. Day
Review Article Drug Experience

Summary

The prevalence and incidence of adverse drug interactions involving nonsteroidal anti-inflammatory drugs (NSAIDs) remains unknown. To identify those proposed drug interactions of greatest clinical significance, it is appropriate to focus on interactions between commonly used and/ or commonly coprescribed drugs, interactions for which there are numerous well documented case reports in reputable journals, interactions validated by well designed in vivo human studies and those affecting high-risk drugs and/or high-risk patients.

While most interactions between NSAIDs and other drugs are pharmacokinetic, NSAID-related pharmacodynamic interactions may be considerably more important in the clinical context, and prescriber ignorance is likely to be a major determinant of many adverse drug interactions. Prescribing NSAIDs is relatively contraindicated for patients on oral anticoagulants due to the risk of haemorrhage, and for patients taking high-dose methotrexate due to the dangers of bone marrow toxicity, renal failure and hepatic dysfunction. Combination NSAID therapy cannot be justified as toxicity may be increased without any improvement in efficacy. Where lithium or anti-hypertensives are coprescribed with NSAIDs, close monitoring is mandatory for lithium toxicity and hypertension, respectively, and aspirin (acetylsalicylic acid) or sulindac are preferred. Phenytoin or oral hypoglycaemic agents may be administered with NSAIDs other than pyrazoles and salicylates provided that patients are monitored carefully at the initiation and cessation of NSAID treatment. Digoxin, aminoglycosides and probenecid may be coprescribed with NSAIDs, but close monitoring is required, particularly for high-risk patients such as the elderly. Indomethacin and triamterene should be avoided due to the risk of renal failure. High dose aspirin should be replaced by naproxen in patients on valproic acid (sodium Valproate) and care is required when corticosteroids are administered to patients taking salicylates long term in high dosage. Interactions between NSAIDs and antacids or cholestyramine are generally avoidable.

Adverse drug interactions involving NSAIDs may be limited by rational prescribing and by careful monitoring, particularly for high-risk patients, drugs and therapy periods.

Keywords

Warfarin Indomethacin Clinical Pharmacology Salicylate Naproxen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abate MA, Layne RD, Neely JL, Ds’Alessandri R. Effect of naproxen and sulindac on blood pressure response to atenolol. DICP: Annals of Pharmacotherapy 24: 810–813, 1990PubMedGoogle Scholar
  2. Abbott FS, Kassam J, Orr JM, Farrell K. The effect of aspirin on valproic acid metabolism. Clinical Pharmacology and Therapeutics 40: 94–100, 1986PubMedGoogle Scholar
  3. Adams JD, Hunter GA. Drug interactions in psoriasis. Australian Journal of Dermatology 17: 39–40, 1976Google Scholar
  4. Adams SS, Buckler JW. Ibuprofen and flurbiprofen. In Huskisson (Ed.) Anti-rheumatic drugs, clinical pharmacology and therapeutic series, Vol. 3, pp. 243–263, Praeger Scientific, Eastbourne and New York, 1983Google Scholar
  5. Aggeler PM, Os’Reilly RA, Leong L, Kowitz PE. Potentiation of anticoagulant effect of warfarin by Phenylbutazone. New England Journal of Medicine 276: 496–501, 1976Google Scholar
  6. Aiken JW, Vane JR. Intrarenal Prostaglandin release attenuates the renal vasoconstrictor activity of angiotensin. Journal of Pharmacology and Experimental Therapeutics 184: 678–687, 1973PubMedGoogle Scholar
  7. Andreasen PB, Simonsen K, Brocks K, Dimo B, Bouchelouche P. Hypoglycaemia induced by azapropazone-tolbutamide interaction. British Journal of Clinical Pharmacology 12: 581–583, 1981PubMedGoogle Scholar
  8. Aronson JK, Grahame-Smith DG. Clinical pharmacology: adverse drug interactions. British Medical Journal 282: 288–291, 1981PubMedGoogle Scholar
  9. Australian Department of Community Services and Health. Annual Report 1988/89, Statistical Supplement 48, table 73, September, 1989Google Scholar
  10. Baber N, Halliday L, Sibeon R, Littler T, Orme MLs’E. The interaction between indomethacin and probenecid: a clinical and pharmacokinetic study. Clinical Pharmacology and Therapeutics 24: 298–306, 1978PubMedGoogle Scholar
  11. Bachmann KA, Schwartz JI, Forney RB, Jauregui L, Sullivan TJ. Inability of Ibuprofen to alter single dose Phenytoin disposition. British Journal of Clinical Pharmacology 21: 165–169, 1986PubMedGoogle Scholar
  12. Baer PA, Shore A, Ikeman RL. Transient fall in serum salicylate levels following intra-articular injection of steroid in patients with rheumatoid arthritis. Arthritis and Rheumatism 30: 345–347, 1987PubMedGoogle Scholar
  13. Banfield C, Os’Reilly R, Chan E, Rowland M. Phenylbutazone-warfarin interaction in man: further stereochemical and metabolic considerations. British Journal of Clinical Pharmacology 16: 669–675, 1983PubMedGoogle Scholar
  14. Baum C, Kennedy DL, Forbes MB. Utilization of nonsteroidal antiinflammatory drugs. Arthritis and Rheumatism 28: 686–692, 1985PubMedGoogle Scholar
  15. Birkett DJ. Drug interactions that matter in general practice. Current Therapeutics 26: 17–20, 1985Google Scholar
  16. Blackshear JL, Davidman M, Stillman MT. Identification of risk for renal insufficiency from nonsteroidal anti-inflammatory drugs. Archives of Internal Medicine 143: 1130–1134, 1983PubMedGoogle Scholar
  17. Blackshear JL, Napier JS, Davidman M, Stillman MT. Renal complications of nonsteroidal antiinflammatory drugs: identification and monitoring of those at risk. Seminars in Arthritis and Rheumatism 14: 163–175, 1985PubMedGoogle Scholar
  18. Blum RA, Watson WA. Ageing and nonsteroidal antiinflammatory drug-induced renal dysfunction. DICP: Annals of Pharmacotherapy 23: 74–75, 1989PubMedGoogle Scholar
  19. Bouchier IAD, Williams HS. Determination of faecal blood loss after confirmed alcohol and sodium acetylsalicylate intake. Lancet 1: 178–180, 1969PubMedGoogle Scholar
  20. Brater DC. Drug-drug and drug-disease interactions with nonsteroidal anti-inflammatory drugs. American Journal of Medicine 80 (Suppl. 1A): 62–77, 1986PubMedGoogle Scholar
  21. Brater DC. Clinical pharmacology of NSAIDs. Journal of Clinical Pharmacology 28: 518–523, 1988PubMedGoogle Scholar
  22. Brodie MJ, Feely J. Adverse drug interactions. British Medical Journal 296: 845–849, 1988PubMedGoogle Scholar
  23. Brogden RN. Nonsteroidal anti-inflammatory analgesics other than salicylates. Drugs 32 (Suppl. 4): 27–45, 1986PubMedGoogle Scholar
  24. Brogden RN, Heel RC, Speight TM, Avery GS. Fenbufen: a review of its pharmacological properties and therapeutic use in rheumatic diseases and acute pain. Drugs 21: 1–22, 1981PubMedGoogle Scholar
  25. Brooks PM, Bell MA, Mason DI, Buchanan WW. Interactions of antirheumatic drugs. Agents and Actions 7 (Suppl. 1): 85–95, 1977Google Scholar
  26. Brooks PM, Bell MA, Sturrock RD, Famay JP, Dick WC. The clinical significance of the indomethacin-probenecid interaction. British Journal of Clinical Pharmacology 1: 287–290, 1974PubMedGoogle Scholar
  27. Brooks PM, Watkins CF, Sturrock RD, Lee P. Clinical evaluation of tolmetin. Current Medical Research Opinion 2: 323–328, 1974Google Scholar
  28. Bruni G, Groppi G, Fanfani A, Sacchetti G. Indoprofen: a review of human studies. In Huskisson (Ed.) Anti-rheumatic drugs: Clinical Pharmacology and Therapeutic Series, Vol. 3, pp. 279–306, Praeger Scientific, Eastbourne and New York, 1983Google Scholar
  29. Bull J, Mackinnon J. Phenylbutazone and anticoagulant control. Practitioner 215: 767, 1975PubMedGoogle Scholar
  30. Burr MI, King S, Davies HEF, Pathy MS. The effects of discontinuing long term diuretic therapy in the elderly. Age and Ageing 6: 38–42, 1977PubMedGoogle Scholar
  31. Cadieux RJ. Drug interactions in the elderly. Postgraduate Medicine 86: 179-184, 186, 1989Google Scholar
  32. Calvo MV, Dominguez-Gil A. Interaction of naproxen with cholestyramine. Biopharmaceutics and Drug Disposition 5: 33–42, 1984Google Scholar
  33. Cardoe N. A double-blind cross-over study to compare the efficacy of three dosage levels of flurbiprofen in the treatment of rheumatoid disease and Osteoarthritis. Current Medical Research Opinion 5: 99–105, 1977Google Scholar
  34. Chalmers JP, West MJ, Wing LM, Bune AJ, Graham JR. Effects of indomethacin, sulindac, naproxen, aspirin and paracetamol in treated hypertensive patients. Clinical and Experimental Hypertension 6A: 1077–1093, 1984Google Scholar
  35. Champion GD. Therapeutic usage of the non-steroidal anti-inflammatory drugs. Medical Journal of Australia 149: 203–213, 1988aPubMedGoogle Scholar
  36. Champion GD. A perspective on the cost-effectiveness risks of non-steroidal anti-inflammatory drug therapy. Medical Journal of Australia 149: 346–349, 1988bPubMedGoogle Scholar
  37. Champion GD, Day RO, Graham GG. Drug interactions with nonsteroidal anti-inflammatory drugs. In Lewis & Furst (Eds) Nonsteroidal anti-inflammatory drugs: mechanisms and clinical use, pp. 245–267, Marcel Dekker, New York, 1987Google Scholar
  38. Chlud K, Kaik B. Clinical studies of the interaction between tolmetin and glibenclamide. International Journal of Clinical Pharmacology 15: 409–410, 1977Google Scholar
  39. Ciabattoni G, Cinotti GA, Pierucci A, Simonetti BM, Manzi M, et al. Effects of sulindac and ibuprofen in patients with chronic glomerular disease. New England Journal of Medicine 310: 279–283, 1984PubMedGoogle Scholar
  40. Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. New England Journal of Medicine 310: 563–572, 1984PubMedGoogle Scholar
  41. Committee on Safety of Medicines. CSM update: non-steroidal anti-inflammatory drugs and serious gastrointestinal reaction 1. British Medical Journal 292: 614, 1986Google Scholar
  42. Crooks J. Rational therapeutics in the elderly. Journal of Chronic Diseases 36: 59–65, 1983PubMedGoogle Scholar
  43. Daly H, Boyle J, Roberts C, Scott G. Interaction between methotrexate and nonsteroidal anti-inflammatory drugs. Lancet 1: 557, 1986PubMedGoogle Scholar
  44. Davis A, Day RO, Begg EJ. Interactions between non-steroidal anti-inflammatory drugs and antihypertensives and diuretics. Australian and New Zealand Journal of Medicine 16: 537–546, 1986PubMedGoogle Scholar
  45. Davis P. Therapeutic options in the selection of nonsteroidal, antiinflammatory drugs in the treatment of Osteoarthritis: a review. Journal of Rheumatology 14 (Suppl. 14): 94–97, 1987PubMedGoogle Scholar
  46. Day RO. Pharmacodynamic interactions of NSAIDs. In Brooks & York (Eds) Proceedings of the XVIth International Congress of Rheumatology, Sydney, May 19–25, 1985, pp. 435–440, Elsevier Science Publishers BV (Biomedical Division), The Netherlands, 1985Google Scholar
  47. Day RO. Drug interactions to be aware of in disease management. In Speight (Ed.) The disease index, pp. 159-164, IMS Publishing, 1991Google Scholar
  48. Day RO, Furst DE, Dromgoole SH, Kamm B, Roe R, et al. Relationship of serum naproxen concentration to efficacy in rheumatoid arthritis. Clinical Pharmacology and Therapeutics 31: 733–740, 1982PubMedGoogle Scholar
  49. Day RO, Graham GG, Champion GD, Lee E. Anti-rheumatic drug interactions. Clinics in Rheumatic Diseases 10: 251–275, 1984PubMedGoogle Scholar
  50. Day RO, Graham GG, Williams KM. Pharmacokinetics of non-steroidal anti-inflammatory drugs. Bailliéres’s Clinical Rheumatology 2: 363–393, 1988bGoogle Scholar
  51. Day RO, Graham GG, Williams KM, Brooks PM. Variability in response to NSAIDs: fact or fiction? Drugs 36: 643–651, 1988aPubMedGoogle Scholar
  52. Day RO, Graham GG, Williams KM, Champion GD, De Jager J. Clinical pharmacology of non-steroidal anti-inflammatory drugs. Pharmacology and Therapeutics 33: 383–433, 1987PubMedGoogle Scholar
  53. Day RO, Harris G, Brown M, Graham GG, Champion GD. Interaction of salicylate and corticosteroids in man. British Journal of Clinical Pharmacology 26: 334–337, 1988cPubMedGoogle Scholar
  54. Diana FJ, Veronich K, Kapoor AL. Binding of non-steroidal anti-inflammatory agents and their effect on binding of racemic warfarin and its enantiomers to human serum albumin. Journal of Pharmaceutical Sciences 78: 195–199, 1989PubMedGoogle Scholar
  55. Donaldson DR, Sreeharan N, Crow MJ, Rajah SM. Assessment of the interaction of warfarin with aspirin and dipyridamole. Thrombosis and Haemostasis 47: 77, 1982PubMedGoogle Scholar
  56. Donker AJ, Arisz L, Brentjens JR, Van der Hem GK, Hollemans HJ. The effect of indomethacin on kidney function and plasma renin activity in man. Nephron 17: 228–296, 1976Google Scholar
  57. Dukes MNG. Health implications of drug interactions. Drug Safety 5 (Suppl. 1): 84–87, 1990PubMedGoogle Scholar
  58. Dupuis LL, Koren G, Shore A, Silverman ED, Laxer RM. Metho-trexate-nonsteroidal anti-inflammatory drug interaction in children with arthritis. Journal of Rheumatology 17: 1469–1473, 1990PubMedGoogle Scholar
  59. Eble JN, West BD, Link KP. A comparison of the isomers of warfarin. Biochemical Pharmacology 15: 1003–1006, 1966Google Scholar
  60. Edelman J, Potter JM, Hackett LP. Effect of intra-articular steroids on plasma salicylate concentrations. British Journal of Clinical Pharmacology 21: 301–307, 1986PubMedGoogle Scholar
  61. Ellison NM, Servi RJ. Acute renal failure and death following sequential intermediate-dose methotrexate and 5-FU: a possible adverse effect due to concomitant indomethacin administration. Neurology 69: 342–343, 1985Google Scholar
  62. Emmanuel JH, Montgomery RD. Gastric ulcer and the antiarthritic drugs. Postgraduate Medical Journal 47: 227–232, 1971PubMedGoogle Scholar
  63. Eriksson L-O, Wahlin-Boll E, Liedholm H, Seideman P, Melander A. Influence of chronic diflunisal treatment on the plasma levels, metabolism and excretion of indomethacin. European Journal of Clinical Pharmacology 37: 7–15, 1989PubMedGoogle Scholar
  64. Ewy G, Kapadia G, Yao L, Lullin M, Marcus F. Digoxin metabolism in the elderly. Circulation 39: 449–453, 1969PubMedGoogle Scholar
  65. Faed EM. Properties of acyl glucuronides: implications for studies of the pharmacokinetics and metabolism of acidic drugs. Drug Metabolism Review 15: 1213–1249, 1984Google Scholar
  66. Favre L, Glasson P, Riondel A, Vallotton MB. Interaction of diuretics and nonsteroidal anti-inflammatory drugs in man. Clinical Science 64: 407–415, 1983PubMedGoogle Scholar
  67. Favre L, Glasson P, Vallotton MB. Reversible acute renal failure from combined triamterene and indomethacin. Annals of Internal Medicine 96: 317–320, 1982PubMedGoogle Scholar
  68. Fenster PE, Comess KA, Hanson CD, Finley PR. Kinetics of the digoxin-aspirin combination. Clinical Pharmacology and Therapeutics 32: 428–430, 1982PubMedGoogle Scholar
  69. Finch MB, Johnston GD, Kelly JG, McDevitt DG. Pharmacokinetics of digoxin alone and in the presence of indomethacin therapy. British Journal of Clinical Pharmacology 17: 353–355, 1984PubMedGoogle Scholar
  70. Fischetti LF. Interaction between nonsteroidal anti-inflammatory drugs and high-dose methotrexate: a literature review. Journal of Pediatric Oncology Nursing 7: 14–16, 1990PubMedGoogle Scholar
  71. Fitzgerald DE, Russel TJ. Voltarol and warfarin, an interaction. In Chiswell & Birdwood (Eds) Current themes in rheumatology, pp. 26–27, Cambridge Medical Publications, Northampton, 1981Google Scholar
  72. Ford DR, Rivers NP, Wood GC. A computerised detection system for potentially significant adverse drug-drug interactions. Journal of the American Pharmaceutical Association 17: 354–357, 1977PubMedGoogle Scholar
  73. Fowler PD. Diclofenac sodium: drug interactions and special studies. Rheumatology and Rehabilitation 17 (Suppl. 2): 60–68, 1979Google Scholar
  74. Fraser DG, Ludden TM, Evans RP, Sutherland III EW. Displacement of Phenytoin from plasma binding sites by salicylate. Clinical Pharmacology and Therapeutics 27: 165–169, 1980PubMedGoogle Scholar
  75. Fries JF, Miller SR, Spitz PW, Williams CA, Hubert HB, et al. Identification of patients at risk for gastropathy associated with NSAID use. Journal of Rheumatology 17 (Suppl 20): 12–19, 1990Google Scholar
  76. Frolich JC, Leftwich R, Ragheb M, Oates JA, Reimann I, et al. Indomethacin increases plasma lithium. British Medical Journal 1: 1115–1116, 1979PubMedGoogle Scholar
  77. Furnell MM, Davies J. The effect of sulindac on lithium therapy. Drug Intelligence and Clinical Pharmacy 19: 374–376, 1985PubMedGoogle Scholar
  78. Furst DE. Clinically important interactions of nonsteroidal anti-inflammatory drugs with other medications. Journal of Rheumatology 15 (Suppl. 17): 58–62, 1988Google Scholar
  79. Geaney DP, Carver JG, Davies CL, Aronson JK. Pharmacokinetic investigation of the interaction of azapropazone with Phenytoin. British Journal of Clinical Pharmacology 15: 727–734, 1983PubMedGoogle Scholar
  80. Gibaldi M, Grundhofer B, Levy G. Time course and dose dependence of antacid effect on urine pH. Journal of Pharmaceutical Sciences 64: 2003–2004, 1975PubMedGoogle Scholar
  81. Gibaldi M, Koup JR. Pharmacokinetic concepts: drug binding, apparent volume of distribution, and clearance. European Journal of Clinical Pharmacology 20: 299–305, 1981PubMedGoogle Scholar
  82. Gibbs S, Waters WE, George CF. The benefits of prescription information leaflets (1). British Journal of Clinical Pharmacology 27: 723, 1989PubMedGoogle Scholar
  83. Gibson T. Nonsteroidal anti-inflammatory drugs: another look. British Journal of Rheumatology 27: 87–90, 1988PubMedGoogle Scholar
  84. Giugliano D, Ds’Onofrio F. Acetylsalicylic acid in human diabetes. In Guidelines to metabolic therapy, Vol. 9(1), pp. 3–4, Upjohn, 1980Google Scholar
  85. Goldszer RC, Coodley EL, Rosner MJ, Simons WM, Schwartz AB. Hyperkalaemia associated with indomethacin. Archives of Internal Medicine 141: 802–804, 1981PubMedGoogle Scholar
  86. Goulden KJ, Dooley JM, Camfield PR, Fraser AD. Clinical val-proate toxicity induced by acetylsalicylic acid. Neurology 37: 1392–1394, 1987PubMedGoogle Scholar
  87. Goulston K, Cooke AR. Alcohol, aspirin and gastrointestinal bleeding. British Medical Journal 4: 664–665, 1968PubMedGoogle Scholar
  88. Green AE, Hort JF, Korn HED, Leach H. Potentiation of warfarin by azapropazone. British Medical Journal 2: 1532, 1977Google Scholar
  89. Griffin JP. Survey of the spontaneous adverse drug reaction reporting schemes in fifteen countries. British Journal of Clinical Pharmacology 22: 83S–100S, 1986PubMedGoogle Scholar
  90. Grimaldi R, Lecchini S, Crema F, Perucca E. In vivo plasma protein binding interaction between valproic acid and na-proxen. European Journal of Drug Metabolism and Pharmacokinetics 9: 359–363, 1984PubMedGoogle Scholar
  91. Guentert TW, Defoin R, Mosberg H. The influence of cholestyramine on the elimination of tenoxicam and piroxicam. European Journal of Clinical Pharmacology 34: 283–289, 1988PubMedGoogle Scholar
  92. Gugler R, Allgayer H. Effects of antacids on the clinical pharmacokinetics of drugs: an update. Clinical Pharmacokinetics 18: 210–219, 1990PubMedGoogle Scholar
  93. Hansten PD, Hayton WL. Effect of antacid and ascorbic acid on serum salicylate concentration. Journal of Clinical Pharmacology 20: 326–331, 1980PubMedGoogle Scholar
  94. Hedqvist P. Effect of Prostaglandins and Prostaglandin synthesis inhibitors on norepinephrine release from vascular tissue. In Robinson & Vane (Eds) Prostaglandin synthetase inhibitors, pp. 303–311, Raven Press, New York, 1974Google Scholar
  95. Holmes GI, Irvin JD, Schrogie JJ, Davies RO, Breault GO, et al. Effects of maalox on the bioavailability of diflunisal. Clinical Pharmacology and Therapeutics 25: 229, 1979Google Scholar
  96. Huskisson EC. Routine drug treatment of rheumatoid arthritis and other rheumatic diseases. Clinics in Rheumatic Diseases 5: 697–706, 1979Google Scholar
  97. Inoue F, Walsh RJ. Folate supplements and phenytoin-salicylate interactions. Neurology 33: 115–116, 1983PubMedGoogle Scholar
  98. Insel PA. Analgesic-antipyretics and antiinflammatory agents. Drugs employed in the treatment of rheumatoid arthritis and gout. In Gilman et al. (Eds) Goodman and Gillmans’s The pharmacological basis of therapeutics, 8th ed., p. 659, Permagon Press, New York, 1990Google Scholar
  99. Isbary J, Doering W, Konig E. Der Einfluss von Tiaprofensaure auf die Digoxinkonzentration im Zerum im Vergleich zu anderen Antirheumatika. Zeitschrift für Rheumatologie 41: 164, 1982Google Scholar
  100. Jain A, McMahon FG, Slatery JT, Levy G. Effect of naproxen on the steady-state concentration and anticoagulant activity of warfarin. Clinical Pharmacology and Therapeutics 25: 61–66, 1979PubMedGoogle Scholar
  101. Johnson AG, Day RO. The problems and pitfalls of NSAID therapy in the elderly (Part II). Drugs & Aging 1: 212–227, 1991aGoogle Scholar
  102. Johnson AG, Day RO. The problems and pitfalls of NSAID therapy in the elderly (Part I). Drugs & Aging 1: 130–143, 1991bGoogle Scholar
  103. Jorgensen HS, Christensen HR, Kampmann JP. Interaction between digoxin and indomethacin or ibuprofen. British Journal of Clinical Pharmacology 31: 108–110, 1991PubMedGoogle Scholar
  104. Juhl RP, Van Thiel DH, Dittert LW, Albert KS, Smith RB. Ibuprofen and sulindac kinetics in alcoholic liver disease. Clinical Pharmacology and Therapeutics 34: 104–109, 1983PubMedGoogle Scholar
  105. Klaassen CD, Watkins JB. Mechanisms of bile formation, hepatic uptake and biliary excretion. Pharmacological Review 36: 1–67, 1984Google Scholar
  106. Klinenberg J, Miller F. Effects of corticosteroids on blood salicylate concentrations. Journal of the American Medical Association 194: 131–134, 1965Google Scholar
  107. Koch-Weser J, Greenblatt DJ. Drug interactions in clinical perspective. European Journal of Clinical Pharmacology 11: 405, 1977PubMedGoogle Scholar
  108. Koopmans PP, Kateman WG, Tan Y, van Ginneken CA, Gribnau FW. The effects of indomethacin and sulindac on hydrochlorothiazide kinetics. Clinical Pharmacology and Toxicology 37: 625–628, 1985Google Scholar
  109. Koren G. Interaction between digoxin and commonly coadministered drugs in children. Pediatrics 75: 1032–1037, 1985PubMedGoogle Scholar
  110. Koren G, Roifman C, Gelfand E, Lavi S, Suria D, et al. Corticosteroids-salicylate interaction in a case of juvenile rheumatoid arthritis. Therapeutic Drug Monitoring 9: 177–179, 1987PubMedGoogle Scholar
  111. Kremer JM, Lee JK. The safety and efficacy of the use of metho-trexate in longterm therapy for rheumatoid arthritis. Arthritis and Rheumatism 29: 822–831, 1986PubMedGoogle Scholar
  112. Kristoff CA, Hayes PE, Barr WH, Small RE, Townsend RJ, et al. Effect of ibuprofen on lithium plasma and red blood cell concentrations. Clinical Pharmacy 5: 51–55, 1986PubMedGoogle Scholar
  113. Kwan KC, Breault GO, Davis RL, Lei BW, Czenvinski AW, et al. Effects of concomitant aspirin administration on the pharmacokinetics of indomethacin in man. Journal of Pharmacokinetics and Biopharmaceutics 6: 451–476, 1978PubMedGoogle Scholar
  114. Kwan TC, Wahba WW, Wildeman RA. Drug interactions: a retrospective study of its epidemiology, clinical significance and influence upon hospitalization. Canadian Journal of Hospital Pharmacy 32: 12–16, 1979PubMedGoogle Scholar
  115. Laiwah ACY, Mactier RA. Antagonistic effect of nonsteroidal anti-inflammatory drugs on furosemide-induced diuresis in cardiac failure. British Medical Journal 283: 714, 1981PubMedGoogle Scholar
  116. Law R, Chambers C. Medicines and elderly people: a general practice survey. British Medical Journal 1: 565–568. 1976PubMedGoogle Scholar
  117. Leftwich RB, Walker LA, Raghels M, Oates JA, Frolich JC. Inhibition of Prostaglandin synthesis increases plasma lithium levels. Clinical Research 26: 291 A, 1978Google Scholar
  118. Leonard RF, Knott PJ, Rankin GO, Robinson DS, Melnick DE. Phenytoin-salicylate interaction. Clinical Pharmacology and Therapeutics 29: 56–60, 1981PubMedGoogle Scholar
  119. Lequesne M. Alternative therapies for high-risk elderly rheumatic patients. Gerontology 34 (Suppl. 1): 33–41, 1988PubMedGoogle Scholar
  120. Lewis RJ, Trager WF, Chan KK, Breckenridge A, Orme M, et al. Warfarin: stereochemical aspects of its metabolism and the interaction with Phenylbutazone. Journal of Clinical Investigation 53: 1607–1617, 1974PubMedGoogle Scholar
  121. Liegler DG, Henderson ES, Hahn MA, Oliverio VT. The effect of organic acids on renal clearance of methotrexate in man. Clinical Pharmacology and Therapeutics 10: 849–857, 1969PubMedGoogle Scholar
  122. Lin JH, Cocchetto DM, Duggan DE. Protein binding as a primary determinant of the clinical pharmacokinetic properties of nonsteroidal anti-inflammatory drugs. Clinical Pharmacokinetics 12: 402–432, 1987PubMedGoogle Scholar
  123. Loftin I, Vesell ES. Interaction between sulindac and warfarin: different results in normal subjects and in an unusual patient with a potassium-losing renal tubular defect. Journal of Clinical Pharmacology 19: 733–742, 1979PubMedGoogle Scholar
  124. Lunde PKM, Rane A, Yaffe SJ, Lunde L, Sjoqvist F. Plasma protein binding of diphenylhydantoin in man: interaction with other drugs and the effect of temperature and plasma dilution. Clinical Pharmacology and Therapeutics 11: 846–855, 1970PubMedGoogle Scholar
  125. Macdonald JI, Herman RJ, Verbeeck RK. Sex-difference and the effect of smoking and oral contraceptive steroids on the kinetics of diflunisal. European Journal of Clinical Pharmacology 38: 175–179, 1990PubMedGoogle Scholar
  126. MacKichen JJ. Pharmacokinetic consequences of drug displacement from blood and tissue proteins. Clinical Pharmacokinetics 9 (Suppl. 1): 32–41, 1984Google Scholar
  127. MacKichan JJ. Protein binding drug displacement interactions: fact or fiction? Clinical Pharmacokinetics 16: 65–73, 1989PubMedGoogle Scholar
  128. Maiche AG. Acute renal failure due to concomitant action of methotrexate and indomethacin. Lancet 1: 1390, 1986PubMedGoogle Scholar
  129. Marcus F. Pharmacokinetic interactions between digoxin and other drugs. Journal of the American College of Cardiology 5: 82A–90A, 1985PubMedGoogle Scholar
  130. Mazanec DJ. Nonsteroidal anti-inflammatory drug therapy: clinical use in a high-risk group — the elderly. Cleveland Clinic Journal of Medicine 55: 419–425, 1988PubMedGoogle Scholar
  131. Mazullo JM. The nonpharmacologic basis of therapeutics. Clinical Pharmacology and Therapeutics 13: 157–158, 1972Google Scholar
  132. McGiff JC, Crowshaw K, Terragno NA, Malik KU, Lonigro AJ. Differential effect of noradrenaline and renal nerve stimulation on vascular resistance in the dog kidney and the release of a Prostaglandin E-like substance. Clinical Science 42: 223–233, 1972PubMedGoogle Scholar
  133. McInnes GT, Brodie MJ. Drug interactions that matter: a critical reappraisal. Drugs 36: 83–110, 1988PubMedGoogle Scholar
  134. Meffin PJ. The effect of renal dysfunction on the disposition of nonsteroidal anti-inflammatory drugs forming acyl-glucuronides. Agents and Actions 17 (Suppl.): 85–89, 1985PubMedGoogle Scholar
  135. Meffin PJ, Veenendaal JR, Brooks PM. Diflunisal-probenecid interaction: Michaelis-Menten kinetics with competitive inhibition. Abstracts of the International Congress of Pharmacology, Tokyo, 0-8, 1981Google Scholar
  136. Meffin PJ, Zilm DM, Veenendaal JR. A renal mechanism for the clofibric acid-probenecid interaction/Journal of Pharmacology and Experimental Therapeutics 227: 739–742, 1983PubMedGoogle Scholar
  137. Mills EH, Whitworth JA, Andrews J, Kincaid-Smith P. Non-ster-oidal anti-inflammatory drugs and blood pressure. Australian and New Zealand Journal of Medicine 12: 478–482, 1982PubMedGoogle Scholar
  138. Miners JO. Drug interactions involving aspirin (acetylsalicylic acid) and salicylic acid. Clinical Pharmacokinetics 17: 327–344, 1989PubMedGoogle Scholar
  139. Miners JO, Grgurinovich N, Whitehead AG, Robson RA, Birkett DJ. Influence of gender and oral contraceptive steroids on the metabolism of salicylic acid and acetylsalicylic acid. British Journal of Clinical Pharmacology 22: 135–142, 1986PubMedGoogle Scholar
  140. Morgan J, Furst DE. Implications of drug therapy in the elderly. Clinics in Rheumatic Diseases 12: 227–244, 1986PubMedGoogle Scholar
  141. Morrison PJ, Rogers HJ, Spector RG, Bradbrook ID, John VA. Effect of pirprofen on glibenclamide kinetics and response. British Journal of Clinical Pharmacology 14: 123–126, 1982PubMedGoogle Scholar
  142. Mortensen ME, Rennebohm RM. Clinical pharmacology and use of nonsteroidal anti-inflammatory drugs. Pediatric Clinics of North America 36: 1113–1139, 1989PubMedGoogle Scholar
  143. Muirden KD, Barraclough DRE. Drug interactions in the management of rheumatoid arthritis. Australian and New Zealand Journal of Medicine 6 (Suppl. 2): 14–17, 1976PubMedGoogle Scholar
  144. Murray MD, Brater DC. Non-steroidal anti-inflammatory drugs. Clinics in Geriatric Medicine 6: 365–397, 1990PubMedGoogle Scholar
  145. National Centre of Drugs and Biologics. Drug utilization in the United States by categories, 1981, 3rd annual review, table V, p. 17, Washington, December, 1982Google Scholar
  146. Neuvonen PJ, Lentovaara R, Bardy A, Elomaa E. Antipyretic analgesics in patients on antiepileptic drug therapy. European Journal of Clinical Pharmacology 15: 263–268, 1979PubMedGoogle Scholar
  147. Nevins M, Berque S, Corwin N. Phenylbutazone and pulmonary oedema. Lancet 2: 1358, 1969PubMedGoogle Scholar
  148. Norman TR, Walker RG, Burrows GD. Renal function related changes in lithium kinetics. Clinical Pharmacokinetics 9: 349–353, 1984PubMedGoogle Scholar
  149. Oates JA. Antagonism of antihypertensive drug therapy by non-steroidal anti-inflammatory drugs. Hypertension 11 (Suppl. 2): II–4–II–6, 1988Google Scholar
  150. Os’Brien B. Patterns of european diagnoses and prescribing. Office of Health Economics, London, 1984Google Scholar
  151. O’Brien WM, Bagby GF. Rare adverse reactions to nonsteroidal antiinflammatory drugs: Part I. Journal of Rheumatology 12: 13–20, 1985PubMedGoogle Scholar
  152. Os’Callaghan JW, Thompson RN, Russell AS. Combining NSAIDs with anticoagulants: yes and no. Canadian Medical Association Journal 131: 857–859, 1984Google Scholar
  153. Os’Reilly RA, Trager WF, Motley CH, Howald W. Stereoselective interaction of Phenylbutazone with (12C13C) warfarin pseu-doracemates in man. Journal of Clinical Investigation 65: 746–753, 1980Google Scholar
  154. Orr JM, Abbott FS, Farrell K, Ferguson S, Sheppard I, et al. Interaction between valproic acid and aspirin in epileptic children: serum protein binding and metabolic effects. Clinical Pharmacology and Therapeutics 31: 642–649, 1982PubMedGoogle Scholar
  155. Patak RV, Mookerjee BK, Bentzel CJ, Hysert PE, Babe JM, et al. Antagonism of the effects of furosemide by indomethacin in normal and hypertensive man. Prostaglandins 10: 649–659, 1975PubMedGoogle Scholar
  156. Patterson AW. Prescribing of anti-rheumatic drugs in general practice. In Dumonde & Jasani (Eds) Recognition of anti-rheumatic drugs, pp. 325–339, MTP Press, Lancaster, 1977Google Scholar
  157. Paxton JW. Effects of aspirin on salivary and serum Phenytoin kinetics in healthy subjects. Clinical Pharmacology and Therapeutics 27: 170–178, 1980PubMedGoogle Scholar
  158. Penner JA, Abbrecht PH. Lack of interaction between ibuprofen and warfarin. Current Therapeutic Research 18: 862–871, 1975PubMedGoogle Scholar
  159. Petrie JC, Howie JGR, Dermo D. Awareness and experience of general practitioners of selected drug interactions. British Medical Journal 2: 262–264, 1974PubMedGoogle Scholar
  160. Piper JM, Ray WA, Daugherty JR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Annals of Internal Medicine 114: 735–740, 1991PubMedGoogle Scholar
  161. Pirson Y, van Ypersele de Strihou C. Renal side effects of nonsteroidal antiinflammatory drugs: clinical relevance. American Journal of Kidney Diseases 8: 338–344, 1986PubMedGoogle Scholar
  162. Pond SM, Birkett DJ, Wade DN. Mechanisms of inhibition of tolbutamide metabolism: Phenylbutazone, oxyphenbutazone, sulphenazole. Clinical Pharmacology and Therapeutics 22: 573–579, 1977PubMedGoogle Scholar
  163. Prescott LF. Clinically important drug interactions. In Avery (Ed.) Drug treatment, 3rd ed., pp. 255–282, ADIS Press, Auckland, 1987Google Scholar
  164. Pucino F, Beck CL, Seifert RL, Strommen GL, Sheldon PA, et al. Pharmacogeriatrics. Pharmacotherapy 5: 314–326, 1985PubMedGoogle Scholar
  165. Puckett WH, Visconti JA. An epidemiological study of the clinical significance of drug-drug interactions in a private community hospital. American Journal of Hospital Pharmacy 28: 247–253, 1971PubMedGoogle Scholar
  166. Puddy IB, Beilin LJ, Vandongen R, Banks R, Rouse I. Differential effects of sulindac and indomethacin on blood pressure in treated essential hypertensive subjects. Clinical Science 69: 327–336, 1985Google Scholar
  167. Pugliese F, Simonetri BM, Cinotti CA, Ciabattoni C, Catella F, et al. Differential interaction of piroxicam and sulindac with the anti-hypertensive effect of Propranolol. European Journal of Clinical Investigation 14: A320, 1984Google Scholar
  168. Quattrocchi FP, Robinson DJ, Curry RW, Grieco ML, Schulman SG. The effect of ibuprofen on serum digoxin concentrations. Drug Intelligence and Clinical Pharmacy 17: 286–288, 1983PubMedGoogle Scholar
  169. Radack KL, Deck CC, Bloomfield SS. Ibuprofen interferes with the efficacy of antihypertensive drugs. Annals of Internal Medicine 107: 628–635, 1987PubMedGoogle Scholar
  170. Ragheb M. Ibuprofen can increase serum lithium level in lithiumtreated patients. Journal of Clinical Psychiatry 48: 161–163, 1987PubMedGoogle Scholar
  171. Ragheb M. The clinical significance of lithium-nonsteroidal anti-inflammatory drug interactions. Journal of Clinical Psycho-pharmacology 10: 350–354, 1990Google Scholar
  172. Ragheb M, Ban TA, Buchanan D, Frolich JC. Interaction of indomethacin and ibuprofen with lithium in manic patients under a steady-state lithium level. Journal of Clinical Psychiatry 41: 397–398, 1980PubMedGoogle Scholar
  173. Ragheb MA, Powell AL. Lithium interaction with sulindac and naproxen. Journal of Clinical Psychopharmacology 6: 150–154, 1986aPubMedGoogle Scholar
  174. Ragheb MA, Powell AL. Failure of sulindac to increases serum lithium levels. Journal of Clinical Psychiatry 47: 33–34, 1986bPubMedGoogle Scholar
  175. Rainer F, Ulreich A, Klein G. Zur Frage der Interaktionen von nichtsteroidalen Antirheumatika mit Kumarinderivaten, oralen Antidiabetika und anderen Pharmaka. Therapiewoche 29: 6834–6839, 1977Google Scholar
  176. Rainsford KD. Toxicity of currently used anti-inflammatory and anti-rheumatic drugs. In Lewis & Furst (Eds) Newer anti-inflammatory drugs, pp. 215–244, Marcel Dekker, New York, 1987Google Scholar
  177. Ray WA. Prescribing patterns for the elderly: data from the Tennessee Medicaid Program. New research and new concerns for the elderly: Pharmaceuticals for the elderly, pp. 34–39, Pharmaceutical Manufacturers’s Association and Hill and Knowlton Incorporated, Washington, 1986Google Scholar
  178. Reimann IW, Diener U, Frolich JC. Indomethacin but not aspirin increases plasma lithium ion levels. Archives of General Psychiatry 40: 283–286, 1983PubMedGoogle Scholar
  179. Reimann IW, Frolich JC. Effects of diclofenac on lithium kinetics. Clinical Pharmacology and Therapeutics 30: 348–352, 1981PubMedGoogle Scholar
  180. Richardson T, Foster J, Mawer GE. Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects. British Journal of Clinical Pharmacology 22: 43–48, 1986PubMedGoogle Scholar
  181. Ritch AES, Perera WNR, Jones CJ. Pharmacokinetics of azapropazone in the elderly. British Journal of Clinical Pharmacology 14: 116–119, 1982PubMedGoogle Scholar
  182. Rossi AC, Hsu JP, Faich GA. Ulcerogenicity of piroxicam: an analysis of spontaneously reported data. British Medical Journal 294: 147–150, 1987PubMedGoogle Scholar
  183. Ross-Lee LM, Eadie MJ, Heazlewood V, Bochner F, Tyrer JH. Aspirin pharmacokinetics in migraine: the effect of metoclopramide. European Journal of Clinical Pharmacology 24: 777–785, 1983PubMedGoogle Scholar
  184. Roth SH. Anti-ulcer therapy in NSAID gastropathy: a rheumatologists’s perspective. Drug Information Journal 22: 419–424, 1988aGoogle Scholar
  185. Roth SH. Rethinking rheumatic disease therapy. Journal of Rheumatology 16: 1408–1409, 1988bGoogle Scholar
  186. Roth SH. Salicylates revisited: are they still the hallmark of anti-inflammatory therapy? Drugs 36: 1–6, 1988cPubMedGoogle Scholar
  187. Roth SH. Nabumetone: a new NSAID for rheumatoid and Osteoarthritis. Orthopaedic Review 21: 223–227, 1992PubMedGoogle Scholar
  188. Rothschild BM. Haematologic perturbations associated with salicylate. Clinical Pharmacology and Therapeutics 26: 145–152, 1979PubMedGoogle Scholar
  189. Rowland M. Plasma protein binding and therapeutic drug monitoring. Therapeutic Drug Monitoring 2: 29–37, 1980PubMedGoogle Scholar
  190. Rubin A, Rodda BE, Warrick P, Gruber CM, Ridolfo AS. Interactions of aspirin with nonsteroidal anti-inflammatory drugs in man. Arthritis and Rheumatism 16: 635–645, 1973PubMedGoogle Scholar
  191. Runkel R, Mroszcak E, Chaplin M, Sevelius H, Segre E. Naproxen-probenecid interaction. Clinical Pharmacology and Therapeutics 24: 706–713, 1978PubMedGoogle Scholar
  192. Ryan JR, Jain AK, McMahon FG, Vargas R. On the question of an interaction between sulindac and tolbutamide in the control of diabetes. Clinical Pharmacology and Therapeutics 21: 231–233, 1977PubMedGoogle Scholar
  193. Sack KE. Update on NSAIDs in the elderly. Geriatrics 44: 71–90, 1989PubMedGoogle Scholar
  194. Salvetti A, Arzilli F, Pedrinelli R, Beggi P, Motolese M. Interaction between Oxprenolol and indomethacin on blood pressure in essential hypertensive patients. European Journal of Clinical Pharmacology 22: 197–201, 1982aPubMedGoogle Scholar
  195. Salvetti A, Pedrinelli R, Magagna A, Ugenti P. Differential effects of selective and non-selective prostaglandin-synthesis inhibition on the pharmacological responses to Captopril in patients with essential hypertension. Clinical Science 63: 261S–263S, 1982bGoogle Scholar
  196. Savitsky JR, Terzakis T, Bina P, Chiccarelli F, Haynes J. Fenbufen-warfarin interaction in healthy volunteers. Clinical Pharmacology and Therapeutics 27: 284, 1980Google Scholar
  197. Schary WL, Lewis RJ, Rowland M. Warfarin-phenylbutazone interaction in man: a long term multiple dose study. Research Communications in Chemical Pathology and Pharmacology 10: 663–672, 1975PubMedGoogle Scholar
  198. Schimmel MS, Inwood RJ, Eidelman AI, Eylath U. Toxic digitalis levels associated with indomethacin therapy in a neonate. Clinical Pediatrics 19: 768–769, 1980PubMedGoogle Scholar
  199. Schlegel SI, Paulus HE. Non-steroidal and analgesic therapy in the elderly. Clinics in Rheumatic Diseases 12: 245–273, 1986PubMedGoogle Scholar
  200. Sedor JR, Williams SL, Chremos AN, Johnson CL, Dunn MJ. Effects of sulindac and indomethacin on renal Prostaglandin synthesis. Clinical Pharmacology and Therapeutics 36: 85–91, 1984PubMedGoogle Scholar
  201. Segre EJ. Naprosyn metabolism in man. In Christie (Ed.) Naprosyn in the treatment of rheumatic disease, p. 11, Syntex, Maidenhead, 1973Google Scholar
  202. Segre EJ, Sevelius H, Varady J. Effects of antacids on naproxen absorption. New England Journal of Medicine 291: 582–583, 1974PubMedGoogle Scholar
  203. Seideman P. Additive effect of combined naproxen and paracetamol in rheumatoid arthritis. British Journal of Rheumatology, in press, 1993Google Scholar
  204. Seideman P, Melander A. Equianalgesic effects of paracetamol and indomethacin in rheumatoid arthritis. British Journal of Rheumatology 27: 117–122, 1988PubMedGoogle Scholar
  205. Sellers EM. Plasma protein displacement interactions are rarely of clinical significance. Pharmacology 18: 225–227, 1979PubMedGoogle Scholar
  206. Serlin MJ, Mossman S, Sibeon RG, Breckenridge AM. The effect of diflunisal on the steady state pharmacodynamics and phar-macokinetics of warfarin. British Journal of Clinical Pharmacology 9: 287P–288P, 1980aPubMedGoogle Scholar
  207. Serlin MJ, Mossman S, Sibeon RG, Tempero KF, Breckenridge AM. Interaction between diflunisal and warfarin. Clinical Pharmacology and Therapeutics 28: 493–498, 1980bPubMedGoogle Scholar
  208. Shah SJ, Bhandarkar SD, Satoskar RS. Drug interaction between chlorpropamide and nonsteroidal anti-inflammatory drugs, ibuprofen and Phenylbutazone. International Journal of Clinical Pharmacology, Therapy and Toxicology 22: 470–472, 1984Google Scholar
  209. Simborg DW. Medication prescribing on a university medical service — the incidence of drug combinations with potential adverse interactions. Johns Hopkins Medical Journal 139: 23–26, 1976PubMedGoogle Scholar
  210. Simon LS, Mills JA. Nonsteroidal anti-inflammatory drugs. New England Journal of Medicine 302: 1179-1185, 1237–1243, 1980PubMedGoogle Scholar
  211. Singh RR, Malaviya AN, Pandey JN, Guleria JS. Fatal interaction between methotrexate and naproxen. Lancet 1: 1390, 1986PubMedGoogle Scholar
  212. Sjoqvist F, Alexanderson B. Drug interactions: a critical look at their documentation and clinical importance. In Baker & Neuhaus (Eds) Proceedings of the European Society for the Study of Drug Toxicity: Toxicological problems of drug combinations, Vol. 13, p. 167, Excerpta Medica, Amsterdam, 1972Google Scholar
  213. Skeith MD, Simkin PA, Healey LA. The renal excretion of indomethacin and its inhibition by probenecid. Clinical Pharmacology and Therapeutics 9: 89–93, 1968PubMedGoogle Scholar
  214. Sloan RW. Drug interactions. In Practical geriatric therapeutics, pp. 39–50, Medical Economics Books, Oradell, 1986Google Scholar
  215. Smith MD, Kupa A, Weatherall M, Henstridge JD, Brooks PM. The effect of tiaprofenic acid on blood pressure control in treated hypertensive patients. Current Medical Research and Opinion 9: 388–393, 1985PubMedGoogle Scholar
  216. Soda DM, Levy G. Inhibition of drug metabolism by hydroxylated metabolites: cross-inhibition and specificity. Journal of Pharmaceutical Sciences 64: 1928–1931, 1975PubMedGoogle Scholar
  217. Spahn H, Benet LZ. Influence of probenecid on the glucuronidation of naproxen enantiomers by hepatic UDP-glucuronyl-transferases in rat liver microsomes. Pharmaceutical Research 4 (Suppl.): S111, 1987Google Scholar
  218. Spahn H, Spahn I, Benet LZ. Probenecid-induced changes in the clearance of carprofen enantiomers: a preliminary study. Clinical Pharmacology and Therapeutics 45: 500–505, 1989PubMedGoogle Scholar
  219. Steiness E, Waldorff S. Different interactions of indomethacin and sulindac with thiazides in hypertension. British Medical Journal 285: 1702–1703, 1982PubMedGoogle Scholar
  220. Stewart CF, Evans WE. Drug-drug interactions with antirheu-matic agents: review of selected clinically important interactions. Journal of Rheumatology 17 (Suppl. 22): 16–23, 1990Google Scholar
  221. Stewart CF, Fleming RA, Arkin CR, Evans WE. Coadministration of naproxen and low-dose methotrexate in patients with rheumatoid arthritis. Clinical Pharmacology and Therapeutics 47: 540–546, 1990PubMedGoogle Scholar
  222. Stoeckel K, Trueb V, Dubach UC, Heintz RC, Ascalone V, et al. Lack of effect of tenoxicam on glibenclamide kinetics and response. British Journal of Clinical Pharmacology 19: 249–254, 1985PubMedGoogle Scholar
  223. Stokes GS, Brooks PM, Johnston HJ, Monaghan JC, Okoro EO, et al. The effects of sulindac and diclofenac in essential hypertension controlled by treatment with a beta-blocker and/or diuretic. Clinical and Experimental Hypertension [A] 13: 1169–1178, 1991Google Scholar
  224. Stowers JM, Constable LW, Hunter RB. Clinical and pharmacological comparisons of chlorpropamide and other sulfonylureas. Annals of the New York Academy of Sciences 74: 689–695, 1959PubMedGoogle Scholar
  225. Tempero KF, Cirrillo VJ, Steelman SL. Diflunisal: chemistry, toxicology, experimental and human pharmacology. In Huskisson & Caldwell (Eds) Diflunisal, Royal Society of Medicine International Congress and Symposium Series, pp. 1–18, Academic Press, London, 1978Google Scholar
  226. Thyss A, Milano G, Kubar J, Namer M, Schneider M. Clinical and pharmacokinetic evidence of a life-threatening interaction between methrotrexate and ketoprofen. Lancet 1: 256–258, 1986PubMedGoogle Scholar
  227. Tobert JA, DeSchepper P, Tjandramaga TB, Mullie A, Buntinx AP, et al. Effect of antacids on the bioavailability of diflunisal in the fasting and postprandial states. Clinical Pharmacology and Therapeutics 30: 385–389, 1981PubMedGoogle Scholar
  228. Tonkin AL, Wing LMH. Interactions of non-steroidal anti-inflammatory drugs. Baillières’s Clinical Rheumatology 2: 455–483, 1988Google Scholar
  229. Toon S, Low LK, Gibaldi M, Trager WF, Os’Reilly RA, et al. The warfarin-sulfinpyrazone interaction: stereochemical considerations. Clinical Pharmacology and Therapeutics 39: 15–24, 1986PubMedGoogle Scholar
  230. Upton RA, Williams RL, Buskin JN, Jones RM. Effects of probenecid on ketoprofen kinetics. Clinical Pharmacology and Therapeutics 31: 705–712, 1982PubMedGoogle Scholar
  231. Van Den Ouweland FA, Gribnau FW, Meyboom RH. Congestive heart failure due to non-steroidal anti-inflammatory drugs in the elderly. Age and Ageing 17: 8–16, 1988PubMedGoogle Scholar
  232. Van Hecken A, Verbesselt R, Tjandramaga TB, De Schepper PJ. Pharmacokinetic interaction between indomethacin and diflunisal. European Journal of Clinical Pharmacology 36: 507–512, 1989PubMedGoogle Scholar
  233. Vane JR, McGiff JC. Possible contributions of endogenous Prostaglandins to the control of blood pressure. Circulation Research 36, 37 (Suppl.): 1-68, 1–75, 1975Google Scholar
  234. Verbeeck RK. Pathophysiologic factors affecting the pharmacokinetics of non-steroidal anti-inflammatory drugs. Journal of Rheumatology 15 (Suppl. 17): 44–57, 1988Google Scholar
  235. Verbeeck RK. Pharmacokinetic drug interactions with nonsteroidal anti-inflammatory drugs. Clinical Pharmacokinetics 19: 44–66, 1990PubMedGoogle Scholar
  236. Verbeeck RK, Tjandramaga TB, Mullie A, Verbesselt R, De Schepper PJ. Effect of aluminium hydroxide on diflunisal absorption. British Journal of Clinical Pharmacology 7: 519–522, 1979PubMedGoogle Scholar
  237. Verbeeck RK, Wallace SM, Loewen GR. Reduced elimination of ketoprofen in the elderly is not necessarily due to impaired glucuronidation. British Journal of Clinical Pharmacology 17: 783–784, 1984PubMedGoogle Scholar
  238. Vesell ES, Passananti T, Johnson AO. Failure of indomethacin and warfarin to interact in normal human volunteers. Journal of Clinical Pharmacology 15: 486–495, 1975PubMedGoogle Scholar
  239. Vestal RE. Drug use in the elderly: a review of problems and special considerations. Drugs 16: 358–382, 1978PubMedGoogle Scholar
  240. Vestal RE. Geriatric clinical pharmacology: an overview. In Vestal (Ed.) Drug therapy in the elderly, pp. 12–28, ADIS Health, Science Press, Sydney, 1984Google Scholar
  241. Walbridge DG, Bazire SR. An interaction between lithium carbonate and Piroxicam presenting as lithium toxicity. British Journal of Psychiatry 147: 206–207, 1985PubMedGoogle Scholar
  242. Waller DG, Waller D. Hypoglycaemia due to azapropazone-tolbutamide interaction. British Journal of Rheumatology 23: 24–25, 1984PubMedGoogle Scholar
  243. Walt R, Katschinski B, Logan R, Ashley J, Langman M. Rising frequency of ulcer perforation in elderly people in the United Kingdom. Lancet 1: 489–492, 1986PubMedGoogle Scholar
  244. Watkins J, Abbott EC, Hensby CN, Webster J, Dollery CT. Attenuation of hypotensive effect of Propranolol and thiazide diuretics by indomethacin. British Medical Journal 281: 702–705, 1980PubMedGoogle Scholar
  245. Webster J, Petrie JC, McLean I, Hawksworth GM. Flurbiprofen interaction with single doses of atenolol and Propranolol. British Journal of Clinical Pharmacology 18: 861–866, 1984PubMedGoogle Scholar
  246. Weinberg MS, Quigg RJ, Salant DJ, Bernard DB. Anuric renal failure precipitated by indomethacin and triamterene. Nephron 40: 216–218, 1985PubMedGoogle Scholar
  247. Weinblatt ME. Drug interactions with non-steroidal anti-inflammatory drugs. Scandinavian Journal of Rheumatology (Suppl. 83): 7–10, 1989Google Scholar
  248. Weinblatt ME, Trentham DE, Fraser PA, Holdsworth DE, Falchuk KR, et al. Longterm prospective trial of low-dose metho-trexate in rheumatoid arthritis. Arthritis and Rheumatism 31: 167–175, 1988PubMedGoogle Scholar
  249. Weintraub M, Jacox RF, Angevine CD, Antwater EC. Piroxicam (CP 16171) in rheumatoid arthritis: a controlled clinical trial with novel assessment techniques. Journal of Rheumatism 4: 393–404, 1977Google Scholar
  250. Whiting B, Williams RL, Lorenzi M, Varady JC, Robins DS. Effect of naproxen on glucose metabolism and tolbutamide kinetics and dynamics in maturity onset diabetics. British Journal of Clinical Pharmacology 11: 295–302, 1981PubMedGoogle Scholar
  251. Whitsett TL, Barry JP, Czerwinski AW, Hall WH, Hampton JW. Tolmetin and warfarin: a clinical investigation to determine if interaction exists. In Ward (Ed.) Tolmetin: a new non-steroidal anti-inflammatory agent, pp. 134–141, Excerpta Medica, Princeton, 1975Google Scholar
  252. Wilkinson GR. Drug distribution and renal excretion in the elderly. Journal of Chronic Disease 36: 91–102, 1983Google Scholar
  253. Williams JRB, Griffin JP, Parkins A. Effect of concomitantly administered drugs on the control of long-term anticoagulant therapy. Quarterly Journal of Medicine NS45: 63–73, 1976Google Scholar
  254. Wills RJ, Velagapudi RB, Puri SK, Yakatan GJ. Effect of food and antacid on the absorption of fendosal. Biopharmaceutics and Drug Disposition 6: 43–50, 1985Google Scholar
  255. Wing LMH. NSAIDs: interactions with antihypertensives and diuretics. Agents and Actions 17 (Suppl.): 91–97, 1985PubMedGoogle Scholar
  256. Wing LM, Bune AJ, Chalmers JP, Graham JR, West MJ. The effects of indomethacin in treated hypertensive patients. Clinical and Experimental Pharmacology and Physiology 8: 537–541, 1981PubMedGoogle Scholar
  257. Wong DG, Lamki LM, Spence JD, Freeman D, McDonald JW. Effect of non-steroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics. Lancet 1: 997–1001, 1986PubMedGoogle Scholar
  258. Yoovathaworn KC, Sriwatanakul K, Thithapandha A. Influence of caffeine on aspirin pharmacokinetics. European Journal of Drug Metabolism and Pharmacokinetics 11: 71–76, 1986PubMedGoogle Scholar
  259. Yu TF, Perel J. Pharmacokinetic and clinical studies of carprofen in gout. Journal of Clinical Pharmacology 20: 347–351, 1980PubMedGoogle Scholar

Copyright information

© Adis International Limited 1993

Authors and Affiliations

  • Anthony G. Johnson
    • 1
    • 2
    • 3
  • Peter Seideman
    • 1
    • 2
    • 3
  • Richard O. Day
    • 1
    • 2
    • 3
  1. 1.Department of Clinical Pharmacology and ToxicologySt Vincents’s HospitalDarlinghurstAustralia
  2. 2.School of Physiology and PharmacologyUniversity of New South WalesSydneyAustralia
  3. 3.Karolinska Institute, Department of RheumatologyDanderyd HospitalDanderydSweden

Personalised recommendations